Shares up nearly 3% (Il Sole 24 Ore Radiocor) - Paris, 05 Sep - Shares in BioMerieux were sharply higher after the French provider of in vitro diagnostics increased its full-year guidance.

At 1036 GMT, BioMerieux was up 2.91% at 106.0 euros.

The company said that in the first half organic sales rose 9.9% to 1.902 billion euros.

Contributive operating income before non-recurring items (CEBIT) reached 306 million euros for the first half of the year, up 20% like for like. The margin improved by 155 basis points at constant exchange rates.

Net income increased 33% to 215 million euros.

BioMerieux now expects sales to grow organically by 8-10%, compared with a previous estimate of a 6-8% rise, and CEBIT to grow by 12-7% organically, against a prior guidance of an least 10% growth. The full year exchange rates impact is expected to be negative in the range of 70 million euros, up from a previous estimate of 50 million euros.

The rise in the company's guidance should lead to a low-single-digit upgrade in the market consensus, according to Berenberg analyst Odysseas Manesiotis.

AAA-Web

(RADIOCOR) 05-09-24 12:42:55 (0291) 5 NNNN